



P.17019/01/2020-PvPI

Indian Pharmacopoeia Commission

National Coordination Centre-Pharmacovigilance Programme of India

(Ministry of Health & Family Welfare, Govt. of India)

Email: pvpi.ipc@gov.in, lab.ipc@gov.in, Website: www.ipc@gov.in, Tel. No. 0120-2783400

Sector-23, Raj Nagar,
Ghaziabad-201002, U.P.
Dated: 5th October, 2020.

Monthly Drug Safety Alert

The preliminary analysis of Adverse Drugs Reactions from the PvPI database reveals that the following drug is associated with the risk as given below.

Table

Sl. No	Suspected Drug	Indication	Adverse Drug Reaction
1	Clindamycin	Antibiotic-Indicated in the treatment of gram +ve organism pathogens, staphylococcus & streptococci, pneumococci.	Symmetrical Drug Related Intertriginous and Flexural Exanthema (SDRIFE)

Healthcare Professionals, Patients/Consumers are advised to closely monitor the possibility of the above ADR associated with the use of above drug. If such reaction is encountered, please report to the NCC-PvPI, IPC by filling of Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>), through Android Mobile App “ADR PvPI App” and PvPI Helpline No. 1800-180-3024.